Methodology of a new inflammatory arthritis registry: TReasure

Abstract

Background/aim: The TReasure registry, created in 2017, is an observational multicenter cohort that includes inflammatory arthritispatients. This article reviews the methodology and objectives of the TReasure registry established to collect data from rheumatoidarthritis (RA) and spondyloarthritis (SpA) patients.Methodology: Fifteen rheumatology centers in Turkey will contribute data to the TReasure database. The actual proprietor of thedatabase is the Hacettepe Rheumatology Association (HRD) and Hacettepe Financial Enterprises. Pharmaceutical companies thatoperate in Turkey (in alphabetical or er), Abbvie, Amgen, BMS, Celltrion Healthcare, Novartis, Pfizer, Roche, and UCB, support theTReasure registry. TReasure is a web-based database to which users connect through a URL (https://www.trials-network.org/treasure)with their unique identifier and passwords provided for data entry and access. TReasure records demographic and clinical features,comorbidities, radiology and laboratory results, measures of disease activity, and treatment data.Discussion: TReasure will provide us with various types of data, such as a cross-sectional view of the current nationwide status of thepatients currently receiving these treatments, and retrospective data as much as allowed by the participating centers’ records. Finally, ahigh-quality prospective dataset will be built over the ensuing years from patients with a new diagnosis of RA or SpA.